Silo Pharma, Inc. announced that it has entered into an exclusive global license agreement to further develop, manufacture, and commercialize its Alzheimer's drug SPC-14. Silo intends to utilize the FDA's streamlined 505(b)(2) pathway for SPC-14, which would shorten clinical timelines and reduce drug development costs. Silo Pharma recently announced a similar exclusive license agreement for its lead drug candidate, SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.93 USD | +80.37% | +132.51% | +39.22% |
03:22pm | Sector Update: Health Care Stocks Rise Pre-Bell Tuesday | MT |
03:06pm | Sector Update: Health Care | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+39.22% | 3.94M | |
+7.40% | 101B | |
+7.76% | 42.18B | |
-13.12% | 32.26B | |
+81.37% | 29.79B | |
-11.37% | 16.06B | |
+1.60% | 14.45B | |
-8.56% | 12.01B | |
+182.74% | 10.71B | |
+3.67% | 8.89B |
- Stock Market
- Equities
- SILO Stock
- News Silo Pharma, Inc.
- Silo Pharma, Inc. Secures Exclusive Global License for Alzheimer's Therapeutic